Literature DB >> 24177313

Docetaxel-nicotinamide complex-loaded nanostructured lipid carriers for transdermal delivery.

Xiucong Fan1, Jinjin Chen, Qi Shen.   

Abstract

Docetaxel (DTX) proved one of the most effective active pharmaceutical ingredients (APIs) for the treatment of cancers. However, in respect of its low solubility and high lipophilic property, nicotinamide (NCT) was chosen as the co-former to form the docetaxel-nicotinamide complex to handle the drawbacks. As was analyzed by Fourier Transform Infrared spectrometer, thermal analysis and saturated solubility, the complex proved stable. Then, docetaxel-nicotinamide complex nanostructured lipid carriers (DN-NLCs) were prepared by emulsion-evaporation at low temperature method. The average drug entrapment efficiency, particle size and drug loading of docetaxel-NLCs (D-NLCs) and DN-NLCs were 81.41-79.48%, 61.45-59.48nm and 1.60-1.63%, respectively. The physicochemical characteristics of nanoparticles were valued by transmission electron microscope and Powder X Ray Diffraction. The in vitro drug-release profile of nanoparticle formulations fitted the Weibull dynamic equation. The skin permeability test was performed by Vertical Franz-type diffusion cells. It demonstrated that DN-NLCs transported drugs more easily than D-NLCs. Confocal Laser Scanning Microscopy observation showed DN-NLCs permeated more effectively than D-NLCs. In vivo study demonstrated that DN-NLCs maintained most in the skin. These results suggest that the DN-NLCs can be a useful method to increase skin permeation of docetaxel. Crown
Copyright © 2013. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Docetaxel; Docetaxel–nicotinamide complex; Nanostructured lipid carriers; Transdermal drug delivery

Mesh:

Substances:

Year:  2013        PMID: 24177313     DOI: 10.1016/j.ijpharm.2013.10.036

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

1.  Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy.

Authors:  Chun-Ying Qu; Min Zhou; Ying-wei Chen; Mei-mei Chen; Feng Shen; Lei-Ming Xu
Journal:  Int J Nanomedicine       Date:  2015-06-10

2.  Sequential release of salidroside and paeonol from a nanosphere-hydrogel system inhibits ultraviolet B-induced melanogenesis in guinea pig skin.

Authors:  Li-Hua Peng; Shen-Yao Xu; Ying-Hui Shan; Wei Wei; Shuai Liu; Chen-Zhen Zhang; Jia-He Wu; Wen-Quan Liang; Jian-Qing Gao
Journal:  Int J Nanomedicine       Date:  2014-04-16

3.  Tacrolimus nanoparticles based on chitosan combined with nicotinamide: enhancing percutaneous delivery and treatment efficacy for atopic dermatitis and reducing dose.

Authors:  Kaiyue Yu; Yixuan Wang; Tao Wan; Yuanhao Zhai; Sisi Cao; Wenyi Ruan; Chuanbin Wu; Yuehong Xu
Journal:  Int J Nanomedicine       Date:  2017-12-22

Review 4.  Magnetite nanostructures as novel strategies for anti-infectious therapy.

Authors:  Ioannis Liakos; Alexandru Mihai Grumezescu; Alina Maria Holban
Journal:  Molecules       Date:  2014-08-20       Impact factor: 4.411

5.  Combination of hydrotropic nicotinamide with nanoparticles for enhancing tacrolimus percutaneous delivery.

Authors:  Wenhui Pan; Mengyao Qin; Guoguang Zhang; Yueming Long; Wenyi Ruan; Jingtong Pan; Zushuai Wu; Tao Wan; Chuanbin Wu; Yuehong Xu
Journal:  Int J Nanomedicine       Date:  2016-08-19

6.  Nicotinamide polymeric nanoemulsified systems: a quality-by-design case study for a sustained antimicrobial activity.

Authors:  Ahmed S Zidan; Osama A A Ahmed; Bader M Aljaeid
Journal:  Int J Nanomedicine       Date:  2016-04-12

7.  Microemulsion-based hydrogels for enhancing epidermal/dermal deposition of topically administered 20(S)-protopanaxadiol: in vitro and in vivo evaluation studies.

Authors:  Ki-Taek Kim; Min-Hwan Kim; Ju-Hwan Park; Jae-Young Lee; Hyun-Jong Cho; In-Soo Yoon; Dae-Duk Kim
Journal:  J Ginseng Res       Date:  2017-08-18       Impact factor: 6.060

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.